Aneuvo

ANEUVO operates at the intersection of medical devices, bioelectronics, rehabilitation, and clinical therapeutics, with a narrow focus on neuromodulation for disabling neurological conditions. Its flagship ExaStim Stimulation System is a portable, non-invasive transcutaneous spinal stimulation platform for people living with spinal cord injury. The company differentiates through an integrated product architecture: customizable electrode placement and stimulation parameters, active charge balancing, clinician controls, and a tablet or mobile interface for therapy configuration and monitoring. CE Mark approval reported in April 2025 and FDA Breakthrough Device Designation provide stronger regulatory validation than an early research-only positioning. The company also has six granted patents and three registered trademarks, supporting an identifiable intellectual-property base. The available comparison set does not identify distinct peer companies, so a precise competitor ranking is not possible without speculation. Relative to conventional rehabilitation approaches, ANEUVO’s thesis is to make spinal stimulation more targeted, portable, and usable across clinical and potentially home settings. Its $22 million Series C and 2026 federal healthcare delivery relationship suggest a shift from technology validation toward commercialization and institutional adoption.

ANEUVO’s growth path shows a transition from grant-backed research to venture-financed medical-device commercialization. The company was founded in 2016 and received National Science Foundation grants of $225,000 in 2016, $225,000 in 2020, and $999,999 in 2021. Series A financing was recorded in 2018 and Series B in 2022, although amounts for both rounds are not publicly specified in the available profile. The major capital inflection arrived on Mar 5, 2026 with a $22 million Series C led by Catcher Technology Co., Ltd.; that round accounts for most of the company’s $23.449999 million in reported funding. Regulatory progress provides a second trajectory marker: ExaStim received CE Mark approval in April 2025, following its FDA Breakthrough Device Designation. The August 2026 MellingMedical relationship indicates movement toward distribution or delivery through the federal healthcare system rather than purely clinical development. Hiring for R&D and full-stack and back-end software roles suggests ANEUVO is expanding both device-development capacity and the digital layer around therapy management. With an employee range of 11–50, the company remains relatively small for a regulated-device business, so execution and clinical adoption are likely more important near-term constraints than capital availability.